Article Text

Download PDFPDF

4CPS-065 Experience of immunochemotherapy versus standard treatment in small-cell lung cancer
Free
  1. E Tejedor Tejada1,
  2. M Rodriguez Goicoechea2,
  3. S Cano Dominguez3,
  4. A Cris Cercós4
  1. 1Barcelona Clinic Hospital, Pharmacy, Barcelona, Spain
  2. 2Complejo Hospitalario de Jaen, Pharmacy, Jaen, Spain
  3. 3Hospital Universitario Virgen de Las Nieves, Pharmacy, Granada, Spain
  4. 4Hospital Universitario Doctor Peset, Pharmacy, Valencia, Spain

Abstract

Background and Importance Immunotherapy has emerged as a revolutionary approach to the treatment of small-cell lung cancer. This aggressive form of lung cancer presents significant challenges due to limited therapeutic response and even resistance to and even resistance to conventional chemotherapy. However, the strategy of combining immunotherapy with chemotherapy makes it possible to stimulate a patient‘s own immune system to fight cancer cells, triggering a specific immune response. This novel combination has shown promising results in improving survival and quality of life for survival and quality of life of patients with metastatic MPC in clinical trials.

Aim and Objectives - To evaluate the effectiveness and safety of combination immunochemotherapy in patients with metastatic small cell cancer.

- Compare immunochemotherapy vs standar of care treatment data.

Material and Methods An observational, multicentre, retrospective study was conducted to evaluate the effectiveness and safety of treatments used in patients diagnosed with metastatic MPC. Patient demographics, clinical and treatment variables were collected. Treatment consisted of courses of carboplatin, etoposide and atezolizumab, followed by atezolizumab maintenance. Tumour responses were classified according to RECIST 1.1 response criteria and toxicities were assessed according to common adverse event criteria CTCAE v5.0

Results Data were collected from 63 patients diagnosed with metastatic small cell lung cancer. 50.8% received combination chemotherapy with atezolizumab and carboplatin plus etoposide, while 49.2% received chemotherapy alone.Median overall survival was 7.5 months in the combination arm and 7.3 months in the combination arm. The median progression-free survival was 7.12 months in the combination arm and 3.1 months in the chemotherapy arm. The adverse event rate for the combination was 78.2% vs 75% for chemotherapy. Adverse events in the combination arm were asthenia, neutropenia, anaemia, nausea and nausea, anaemia, nausea and infections

Conclusion and Relevance The combination of atezolizumab with carboplatin and etoposide shows better survival outcomes without increasing toxicity, than standard therapy.

References and/or Acknowledgements 1. Dingemans, Früh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 Jul;32(7):839–85.

Conflict of Interest No conflict of interest.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.